{"id":"thalidomide-dexamethasone","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Neuropathy"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Thalidomide works by binding to and inhibiting the release of TNF-alpha, a key cytokine involved in the inflammatory response. This action helps to reduce inflammation and modulate the immune response, which can be beneficial in treating certain types of cancer. Additionally, thalidomide has been shown to have anti-angiogenic properties, which can help to prevent the growth of new blood vessels that feed tumors.","oneSentence":"Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:22.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Erythema nodosum leprosum"}]},"trialDetails":[{"nctId":"NCT02844309","phase":"PHASE4","title":"The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":44},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT02461888","phase":"PHASE2","title":"Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT07264894","phase":"PHASE4","title":"ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou University","startDate":"2025-12-31","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":30},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT07204041","phase":"PHASE2","title":"Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":40},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01659658","phase":"PHASE3","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-12-26","conditions":"Relapsed or Refractory Systemic Light Chain Amyloidosis","enrollment":177},{"nctId":"NCT05835726","phase":"","title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-01-01","conditions":"Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation","enrollment":188},{"nctId":"NCT06793475","phase":"NA","title":"Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-04-09","conditions":"Extramedullary Multiple Myeloma","enrollment":20},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT00871013","phase":"PHASE2","title":"Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2009-03","conditions":"Myeloma","enrollment":160},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT02541383","phase":"PHASE3","title":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2015-09","conditions":"Multiple Myeloma","enrollment":1085},{"nctId":"NCT01539083","phase":"PHASE3","title":"Velcade (Bortezomib) Consolidation After Transplant","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-01-13","conditions":"Multiple Myeloma","enrollment":256},{"nctId":"NCT06284395","phase":"","title":"Two Schemes Response in Multiple Myeloma","status":"RECRUITING","sponsor":"Hospital General de Mexico","startDate":"2023-11-20","conditions":"Response, Acute Phase, Survivorship","enrollment":83},{"nctId":"NCT04352205","phase":"PHASE2","title":"Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-05-07","conditions":"Plasma Cell Myeloma, Renal Failure","enrollment":17},{"nctId":"NCT06457464","phase":"","title":"Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-07-01","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02586038","phase":"PHASE2","title":"STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS","status":"COMPLETED","sponsor":"Mario Boccadoro","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":175},{"nctId":"NCT02891811","phase":"PHASE2","title":"Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2017-03-10","conditions":"Multiple Myeloma","enrollment":124},{"nctId":"NCT03759093","phase":"PHASE2, PHASE3","title":"CURATE.AI Optimized Modulation for Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2023-09-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03411031","phase":"PHASE2","title":"Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-04","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04941937","phase":"PHASE2","title":"Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM","status":"UNKNOWN","sponsor":"Juan Du","startDate":"2022-01-27","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT01242267","phase":"PHASE1, PHASE2","title":"Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-05-11","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT00054158","phase":"PHASE2","title":"Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2004-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":24},{"nctId":"NCT05561049","phase":"","title":"Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":120},{"nctId":"NCT01849783","phase":"PHASE2","title":"Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Margarida Magalhaes-Silverman","startDate":"2013-04-04","conditions":"Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease","enrollment":41},{"nctId":"NCT02424851","phase":"PHASE2","title":"Optimising Renal Outcome in Myeloma Renal Failure","status":"COMPLETED","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2014-11","conditions":"Multiple Myeloma, Chronic Kidney Disease","enrollment":31},{"nctId":"NCT00075829","phase":"PHASE3","title":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":710},{"nctId":"NCT00256776","phase":"PHASE3","title":"MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2005-07","conditions":"Multiple Myeloma","enrollment":269},{"nctId":"NCT00792142","phase":"PHASE2","title":"Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-01-16","conditions":"Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity","enrollment":45},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04120519","phase":"PHASE2","title":"Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-10-10","conditions":"Langerhans Cell Histiocytosis","enrollment":20},{"nctId":"NCT00538733","phase":"PHASE2","title":"Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":26},{"nctId":"NCT04891744","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With Thalidomide and Dexamethasone in RRMM","status":"UNKNOWN","sponsor":"Li Zheng","startDate":"2021-07-06","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT02545907","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2017-09-14","conditions":"Amyloidosis","enrollment":10},{"nctId":"NCT00907452","phase":"NA","title":"Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2009-07-29","conditions":"Myeloma","enrollment":143},{"nctId":"NCT02085655","phase":"PHASE3","title":"PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma","status":"UNKNOWN","sponsor":"Huiqiang Huang","startDate":"2013-04-25","conditions":"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":264},{"nctId":"NCT00966693","phase":"PHASE1, PHASE2","title":"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08-25","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":77},{"nctId":"NCT00274820","phase":"PHASE2","title":"Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes","enrollment":15},{"nctId":"NCT02733380","phase":"PHASE2","title":"Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2016-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":20},{"nctId":"NCT03608501","phase":"PHASE2","title":"A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2019-09-30","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02410694","phase":"PHASE2","title":"Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2015-04","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT00452569","phase":"PHASE3","title":"Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-02-01","conditions":"Multiple Myeloma","enrollment":499},{"nctId":"NCT00657488","phase":"PHASE2, PHASE3","title":"Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2001-12-01","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT00049374","phase":"PHASE2","title":"Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2002-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT03393273","phase":"PHASE2","title":"Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-20","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT03792620","phase":"PHASE3","title":"Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation","status":"UNKNOWN","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2018-11-20","conditions":"Multiple Myeloma Stage I","enrollment":20},{"nctId":"NCT00038090","phase":"PHASE2, PHASE3","title":"Thalidomide-Dexamethasone for Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2000-06","conditions":"Multiple Myeloma","enrollment":83},{"nctId":"NCT00124579","phase":"PHASE2","title":"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00064337","phase":"PHASE2","title":"S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2004-01","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":104},{"nctId":"NCT03601871","phase":"NA","title":"The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy","status":"UNKNOWN","sponsor":"Yunpeng Liu","startDate":"2018-07-12","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":880},{"nctId":"NCT01526694","phase":"PHASE2","title":"Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM","status":"COMPLETED","sponsor":"Azienda Ospedaliera di Bolzano","startDate":"2012-07","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT03562169","phase":"PHASE3","title":"The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2017-03-20","conditions":"Multiple Myeloma","enrollment":406},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420},{"nctId":"NCT03143036","phase":"PHASE2","title":"Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2018-05-01","conditions":"Relapse and / or Refractory Myeloma","enrollment":100},{"nctId":"NCT00538824","phase":"PHASE2","title":"Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-12","conditions":"Multiple Myeloma","enrollment":5},{"nctId":"NCT02559154","phase":"PHASE4","title":"Modified Bortezomib-based Combination Therapy for Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT03402295","phase":"PHASE3","title":"Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation","status":"COMPLETED","sponsor":"Grupo de Estudos Multicentricos em Onco-Hematologia","startDate":"2009-06-15","conditions":"Multiple Myeloma, Effects of Chemotherapy","enrollment":311},{"nctId":"NCT01057225","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":"Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":64},{"nctId":"NCT00577512","phase":"PHASE2","title":"2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT00083915","phase":"PHASE3","title":"DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-06","conditions":"Multiple Myeloma","enrollment":97},{"nctId":"NCT00574080","phase":"PHASE3","title":"UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-07","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03335098","phase":"PHASE2","title":"Study of VTD in Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-11-21","conditions":"Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma","enrollment":15},{"nctId":"NCT03140943","phase":"PHASE2","title":"Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2017-09-13","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":100},{"nctId":"NCT02966522","phase":"PHASE2","title":"Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-10","conditions":"Cardiac Amyloidosis","enrollment":30},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303},{"nctId":"NCT00113919","phase":"PHASE1, PHASE2","title":"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2004-06","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT02248428","phase":"PHASE3","title":"Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2012-04","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT00222105","phase":"PHASE2","title":"A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2002-11","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT00182663","phase":"PHASE2","title":"Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-06","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":30},{"nctId":"NCT01548573","phase":"PHASE2","title":"Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01133743","phase":"PHASE2","title":"Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT01632150","phase":"PHASE2","title":"Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":51},{"nctId":"NCT00097981","phase":"PHASE3","title":"A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-01","conditions":"Multiple Myeloma","enrollment":225},{"nctId":"NCT00890552","phase":"NA","title":"A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-04","conditions":"Leukemia, Amyloidosis","enrollment":25},{"nctId":"NCT02981199","phase":"NA","title":"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Chen Wenming","startDate":"2016-01","conditions":"Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse","enrollment":80},{"nctId":"NCT00040937","phase":"PHASE2","title":"S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2002-06","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT02203253","phase":"PHASE3","title":"Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting","status":"COMPLETED","sponsor":"China Medical University, China","startDate":"2014-07","conditions":"Neoplasms","enrollment":642},{"nctId":"NCT00892346","phase":"PHASE3","title":"Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT01976195","phase":"PHASE2","title":"High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP","status":"WITHDRAWN","sponsor":"Shandong University","startDate":"2013-10","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT00450008","phase":"PHASE2","title":"Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2006-12","conditions":"Prostatic Neoplasms","enrollment":9},{"nctId":"NCT00023530","phase":"NA","title":"Blood and Marrow Transplant Clinical Research Network","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2001-09","conditions":"Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT00458705","phase":"PHASE2","title":"Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":45},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00450801","phase":"PHASE2","title":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Lymphoma","enrollment":22},{"nctId":"NCT01971658","phase":"PHASE3","title":"Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2013-10","conditions":"Multiple Myeloma","enrollment":358},{"nctId":"NCT00111748","phase":"PHASE3","title":"UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2005-02","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT00057564","phase":"PHASE3","title":"A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2003-02","conditions":"Multiple Myeloma","enrollment":470},{"nctId":"NCT02145715","phase":"PHASE1, PHASE2","title":"Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma","status":"UNKNOWN","sponsor":"Prof Jamie Cavenagh","startDate":"2013-01","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT00522392","phase":"PHASE3","title":"Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":48},{"nctId":"NCT00577096","phase":"NA","title":"Effects of Exercise in Combination With Epoetin Alfa","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-10","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT01527032","phase":"PHASE2","title":"Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"2002-09","conditions":"Amyloidosis","enrollment":""},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DISEASE PROGRESSION"},{"count":1,"reaction":"MUSCULAR WEAKNESS"},{"count":1,"reaction":"PARAPLEGIA"},{"count":1,"reaction":"SPINAL CORD NEOPLASM"}],"_approvalHistory":[],"publicationCount":216,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Thalidomide, Dexamethasone","genericName":"Thalidomide, Dexamethasone","companyName":"Grupo de Estudos Multicentricos em Onco-Hematologia","companyId":"grupo-de-estudos-multicentricos-em-onco-hematologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thalidomide inhibits the release of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammation and immune response. Used for Multiple myeloma, Erythema nodosum leprosum.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}